Skip to content
Menu

Immuron Limited IMRN

Full chart Compare
Set alert

Price alert · IMRN

All alert types
0.90 USD +0.05 (+5.80%)

Regular-session close

0.90 0.00 -0.01%

After hours · Nov 20, 4:00 PM ET

0.815 Day range 0.8999
0.70 52-week range 1.84
YTD
+17.93%
1 year
-44.46%

5D +0.0799 (+9.75%)

0.85000.9000MonTueWedThuFri0.8998
Market cap
7.26M
Revenue (ttm)
4.90M
Profit margin
-141.49%
EPS (ttm)
-0.34
Shares out
5.70M
Forward P/E
-198.54
YTD return
+17.93%
1-year return
-44.46%
Volume
19.70K
Avg volume
2.06M
Open
0.85
Previous close
0.8505
Day's range
0.815 – 0.8999
52-week range
0.70 – 1.84
Beta
1.17
Price target
4.69 (+421.5%)

Key statistics

50-day average
1.96
200-day average
2.38
Enterprise value
435.39M
Price / sales
2.31
Price / book
35.45
Revenue growth
108.60%
Free cash flow
-2.56M
Total cash
11.66M
Total debt
173.50K
Return on equity
-42.92%
Short % of float
0.18%

Fundamental scorecard

10 of 25 checks passed on IMRN’s reported financials

ValueGrowthProfitabilityHealthDividend

10of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
IMRN Revenue — annual 8.88M
IMRN Net income — annual -3.68M
IMRN EPS — annual -0.496

Upgrades / downgrades

IMRN analyst upgrades and downgrades
DateFirmActionFromTo
Sep 26, 2024Litchfield Hillsinit—Buy
Oct 18, 2017HC Wainwright & Co.init—Buy

About Immuron Limited

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Sector
Healthcare
Industry
Biotechnology
Country
Australia

News

Your note

Sign in to keep a note on IMRN — it syncs with the Stock Master app.

Institution ownership

IMRN institution ownership
Holder% heldSharesValueReported
Rhumbline Advisers0.17%5,93911.79KSep 29, 2024
Morgan Stanley0.09%3,3336.62KSep 29, 2024
Stephens Consulting, LLC 0.04%1,5002.98KSep 29, 2024